The Cancer Letter

Inside information on cancer research and drug development

Letter To The Editor

UCSD Moores EAB: A leak to The Cancer Letter derailed the iterative process

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Dear Editor, 

The UCSD Moores Cancer Center External Advisory Board is extremely disappointed in the commentary included in the most recent issue of The Cancer Letter regarding MCC (The Cancer Letter, June 2, 2023).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Carvykti extended OS in r/r MM vs standard therapies in phase III trial

Long-term results from the phase III CARTITUDE-4 study show a single infusion of Carvykti (ciltacabtagene autoleucel) significantly extended overall survival in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor, reducing the risk of death by 45% versus standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone. 
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account